Liu 2008.
Methods |
Parallel randomised controlled clinical trial Comparative study design (2‐sided confidence interval) Randomisation ratio: 1:1 |
|
Participants |
Inclusion criteria: primary hyperuricaemia, blood uric acid concentration > 420 mmol/L (male), > 360 mmol/L (female); TG > 117 mmol/L; age: 18 ‐ 75 years old; participants without using uric acid‐lowering drugs Exclusion criteria: acute gout episode patients; secondary hyperuricaemia patients; patients with severe primary co‐morbidities on heart, liver, renal and blood systems and mental disorders Diagnostic criteria: not mentioned in the original article |
|
Interventions |
Number of study centres: 1 Treatment before study: not mentioned in the original article Titration period: 4 weeks |
|
Outcomes | Outcomes reported in abstract of publication: blood uric acid, TG | |
Study details |
Run‐in period: not mentioned in the original article Study terminated before regular end: no |
|
Publication details |
Language of publication: Chinese Unclear funding Publication status: peer review journal |
|
Stated aim of study | Quote: "To investigate the clinical effectiveness and safety of Zhusuanhuoxue decoction on the patients suffered from primary hyperuricaemia combined with hypertriglyceridaemia." | |
Notes | TG: triglycerides | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Adequate sequence generation | Low risk | Quote: "Random number table was used to distribute the 60 participants to two groups" |
Allocation concealment | Unclear risk | Comment: no detailed information |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Comment: no detailed information |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Comment: no detailed information |
Incomplete outcome data addressed All outcomes | Low risk | Comment: no missing data |
Free of selective reporting | Low risk | Comment: all the prespecified outcomes in the methods section of the article were reported in the results section |
Free of other bias | Unclear risk | Comment: no information on the basic characteristics of the two groups of participants and no information on funding |